Stephen H. Tsang, MD, PhD: MCO-010 for Stargardt Disease in STARLIGHT Trial

In a presentation at AAO 2023, Tsang discussed topline data from the phase 2 trial on MCO-010 optogenetic therapy for vision loss in Stargardt Disease.

Related Keywords

San Francisco ,California ,United States ,American ,Stephenh Tsang , ,American Academy Of Ophthalmology ,Drug Administration ,Columbia University ,Multi Characteristic Opsin ,Stargadt Disease ,Annual American Academy ,Orphan Drug ,Fast Track ,Stargardt Disease ,